<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02557503</url>
  </required_header>
  <id_info>
    <org_study_id>2014KT71</org_study_id>
    <nct_id>NCT02557503</nct_id>
  </id_info>
  <brief_title>Hepatic Arterial Infusion of Oxaliplatin and Fluorouracil Treatment of Advanced Primary Liver Cancer After TACE</brief_title>
  <official_title>An Randomized and Controlled Study of Hepatic Arterial Infusion of Oxaliplatin and Fluorouracil Treatment of Advanced Primary Liver Cancer After TACE</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhu Xu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Cancer Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the therapy effect and security of oxaliplatin and fluorouracil on with or
      without concomitant vascular invasion and extrahepatic metastases unresectable advanced
      primary liver cancer
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>three years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival (OS)</measure>
    <time_frame>three years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Advanced Adult Primary Liver Cancer</condition>
  <arm_group>
    <arm_group_label>Oxaliplatin by HAIC after TACE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To investigate the therapy effect and security of oxaliplatin on with or without concomitant vascular invasion and extrahepatic metastases unresectable advanced primary liver cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluorouracil by HAIC after TACE</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>To investigate the therapy effect and security of fluorouracil on with or without concomitant vascular invasion and extrahepatic metastases unresectable advanced primary liver cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin and fluorouracil</intervention_name>
    <description>Oxaliplatin and fluorouracil by HAIC on with or without concomitant vascular invasion and extrahepatic metastases unresectable advanced primary liver cancer after TACE</description>
    <arm_group_label>Oxaliplatin by HAIC after TACE</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. With written informed consent

          2. Age ranged from 18 to 80 years, both men and women

          3. Confirmed by pathology or clinical diagnosis of liver cancer

          4. Progress systemic chemotherapy or who can not tolerate chemotherapy, or who refuse
             chemotherapy

          5. Never received TACE treatment

          6. (M) RECIST 1.0 criteria measurable liver lesions at several ≥2, each lesion diameter
             ≥3 cm long and ≤20cm,

          7. ECOG PS score of ≤2

          8. expected survival time ≥12 weeks

          9. The test results before 7 days entered the group must meet the following requirements:

        Hemoglobin ≥ 90 g / L Absolute neutrophil count (ANC)&gt; 1,500 / mm3 Platelet count ≥ 80x109
        / L Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) &lt;5 times the
        upper limit of normal (UNL) Total bilirubin &lt;3UNL Serum creatinine &lt;1.5 UNL PT or INR, PPT
        &lt;1.5 UNL (for patients undergoing warfarin or heparin anticoagulant therapy, if there is no
        evidence that there is an abnormality of the above parameters, you can enter the group, but
        must be closely monitored to detect at least once a week until the INR stable)

        Exclusion Criteria:

          1. Specific circumstances of patients not suitable for TACE therapy / chemotherapy

          2. Hepatic decompensation, or the presence of hepatic encephalopathy

          3. Before entering the study with gastrointestinal bleeding within 30 days

          4. Presence of brain metastasis

          5. Pregnant or lactating women

          6. Active bleeding or sepsis

          7. History of heart disease:

             NYHA two or more of congestive heart failure, symptomatic coronary artery disease Need
             to use β-blockers or digoxin medication other than arrhythmias

          8. Despite treatment, still systolic blood pressure&gt; 150 mmHg or diastolic blood
             pressure&gt; 90 mmHg hypertension

          9. Not cure severe trauma, acute or incurable ulcer, or three months fracture

         10. The researchers believe their poor compliance

         11. Exist once or primary lesion or histologically different tumors and colorectal cancer,
             except: head and neck carcinoma in situ, cured basal cell carcinoma, superficial
             bladder cancer (Ta, Tis, T1), and the group 3 years ago, it has been cured of cancer

         12. HIV infection or the presence of AIDS-related illness, or severe acute and chronic
             diseases

         13. Drug abuse, or suffering that could interfere with study compliance and other
             psychological or psychiatric disorders

         14. Need drug therapy epilepsy (such as steroids or antiepileptic drugs

         15. Chemotherapy contraindications exist

         16. Any instability or likely to endanger the patient in this study the safety and
             compliance of the case
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhu Xu, Master</last_name>
      <phone>0086-10-88195476</phone>
      <email>zhux387@263.net</email>
    </contact>
    <investigator>
      <last_name>Zhu Xu, Master</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 22, 2015</study_first_submitted>
  <study_first_submitted_qc>September 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2015</study_first_posted>
  <last_update_submitted>September 22, 2015</last_update_submitted>
  <last_update_submitted_qc>September 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Cancer Hospital</investigator_affiliation>
    <investigator_full_name>Zhu Xu</investigator_full_name>
    <investigator_title>Interventional Therapy Department</investigator_title>
  </responsible_party>
  <keyword>TACE; oxaliplatin; fluorouracil; liver cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

